财经图解 . 以下文章来源于财经图解 ，作者十字路口 消息面上，7月28日晚间，药明康德发布的2025年半年度报告显示，该公司上半年实现营收207.99亿 元，同比增长20.64%；实现归属于上市公司股东的净利润85.61亿元，同比大幅增长101.92%。 同时药明康德上调全年销售预期。公司公告称，预计2025年持续经营业务收入重回双位数增长，增速从 10-15%上调至13-17%，预计全年整体收入从人民币415-430亿元上调至人民币425-435亿元。公司表示， 将持续聚焦CRDMO核心业务，持续提高生产经营效率。 按收入结构来看，药明康德上半年TIDES（寡核苷酸和多肽）业务收入达到人民币50.3亿元，同比增长 141.6%，成为业绩攀升的核心动力。 财经大事早知道，关注东方财富股票！ 周二医药板块中的CXO方向大爆发，药石科技涨超18%，昭衍新药涨停，泰格医药、药明康德、康龙化 成等强势跟涨。拉长时间范围看，年内至今在市值超百亿的CXO个股中，昭衍新药涨幅超111%，位列 第一，药明康德、皓元医药、凯莱英、博腾股份等个股涨幅在83%至60%之间，药石科技、九洲药业、 康龙化成、泰格医药等个股涨幅也均超 ...

Core Viewpoint - The implementation of the childcare subsidy system in China aims to alleviate the burden of raising children and reflects the government's commitment to building a pro-natalist society, addressing the challenges posed by an aging population and declining birth rates [1]. Group 1: Childcare Subsidy Implementation - Starting from January 1, 2025, the Chinese government will provide subsidies for children under three years old, amounting to 3,600 yuan per child per year [1]. - The announcement has sparked discussions on population and childcare issues, highlighting the urgency of addressing declining birth rates and increasing aging population [1]. Group 2: Global Aging Trends - According to the United Nations, the proportion of people aged 65 and older in the global population is projected to rise from 6.8% in 2000 to 14.3% by 2040, indicating a shift into moderate aging [2]. - By 2050, this figure may increase to 16.3%, with projections suggesting it could reach 21% in the latter half of the century, marking a transition into severe aging [2]. - Japan has the highest median age among the top 20 populous countries, at 49.4 years, followed by Germany and Thailand with median ages of 45.3 and 40.1 years, respectively [2].

Core Viewpoint - The article highlights the contrasting paths of China and the United States in the renewable energy sector, with China leading significantly in renewable energy capacity and technology while the U.S. continues to invest heavily in fossil fuels [1][3][7]. Renewable Energy Capacity - In 2024, China's total power generation is projected to reach 10,073 TWh, compared to the U.S. at 4,387 TWh, showcasing China's dominance in renewable energy projects [1][3]. - China's renewable energy accounts for 34% of its total power generation, while the U.S. stands at 24% [1][3]. - Specific renewable energy capacities show China leading in solar (834 TWh vs. 303 TWh), wind (992 TWh vs. 453 TWh), hydro (1354 TWh vs. 236 TWh), and biomass (208 TWh vs. 47 TWh) [2]. Electric Vehicle Market - China exported electric vehicles worth $38 billion in the previous year, three times more than Tesla's annual exports of approximately $12 billion [4]. - The market share of electric vehicles in China has surpassed 50% and is expected to exceed 60% by the end of the year [6]. - The U.S. electric vehicle market is hindered by low charging infrastructure and unstable subsidy policies, while China is rapidly expanding its charging network [4][6]. Battery Technology - China dominates the lithium-ion battery market, with exports reaching $65 billion, which is 22 times that of the U.S. [4][6]. - The article emphasizes that the country with battery manufacturing capabilities will gain significant economic and geopolitical advantages, with China currently being the only winner in this domain [6]. Policy and Strategic Direction - The U.S. is focusing on reviving fossil fuel industries, while China is committed to renewable energy development, as evidenced by significant investments in solar, wind, and hydro projects [3][7]. - Historical patterns show that U.S. energy policies have fluctuated with political changes, while China maintains a consistent long-term strategy for renewable energy [8][10]. Global Influence - China is expanding its influence in the global renewable energy market by investing in projects across various countries, including Hungary, Saudi Arabia, and Indonesia [10]. - The article notes that most countries are not following the U.S. fossil fuel path, instead opting for renewable energy investments, which aligns with China's growing global influence [10].

大A"回宫"！ 以三大股指为例，自2025年4月7日的阶段性低点以来，均斩获了不俗的涨幅。创业板 指"猛拉"超16.5%，上证指数站上3600点，17个申万一级行业的年内涨幅超10%。 数据来源：Ch oi c e，截至2 025- 07 - 2 9；历史行情不预示未来，也不构成对基金业绩表现的保证。市场有风险，投资需谨慎。 大家的账户，有没有悄悄变"胖"？仓位尚低的小伙伴，是否会热血沸腾地翻出私房钱和孩子的压岁 钱，打算抓紧加仓、大干一场？而在此之前，你们会否好奇：这波行情究竟是"牛市"起跑线，还是 阶段性狂欢？ 以下文章来源于富国基金 ，作者以史为鉴 富国基金 . 关注富国基金，获取富国基金独家专业又有料的投资资讯，富二姑娘为您提供专业服务。富国基金，投资未 来 · 在一起。 面对以上"灵魂三问"，大家不必急着回答。在今天的推文中，小编就通过几组数据，来揭示当前市 场的真实位置和"擒牛"线索！ 牛市的"经典剧本" 历史行情回顾 | | 第1轮 | 第2轮 | 第3轮 | 第4轮 | 第5轮 | 本轮 | | --- | --- | --- | --- | --- | --- | --- | | 时间区间 ...

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a significant rebound, with numerous stocks doubling in value and a strong performance from innovative drug companies, indicating a potential for continued growth and investment opportunities [1][2][3]. Group 1: Market Performance - As of July 29, 2023, the pharmaceutical sector has seen 42 stocks double in value this year, with Shuyatain leading at a 560% increase [1]. - Eight stocks, including Saifen Technology and Yipin Hong, have risen over 200%, while over 30 stocks have increased by more than 100% [1]. Group 2: Fund Performance - The surge in the pharmaceutical sector has led to significant gains in several pharmaceutical-themed funds, with many achieving over 100% returns in the past year [2]. - Fund managers believe that innovative drugs are likely to gain traction due to high demand and the upcoming product launches from various A-share and H-share companies [2]. Group 3: Industry Insights - Analysts highlight that the innovative drug sector is entering a golden development phase, supported by short-term performance from research outcomes and long-term benefits from aging populations and health demand upgrades [2]. - The innovative drug sector is seen as the most promising sub-industry within pharmaceuticals, with a clear growth trajectory and investment potential [3]. Group 4: Future Outlook - The innovative drug sector is expected to benefit from a combination of policy support and fundamental growth, leading to a revaluation of the sector [3]. - Analysts recommend continued investment in specific segments such as CRO & CDMO, GLP-1, and unique raw materials, which are anticipated to show strong performance [3].

由天天基金独家播出的《下半年配置诊疗室》直播特别策划现已正式上线！ 长按下方二维码 或 点击文末阅 读原文 提前锁定心仪场次，预约直播不迷路！ 更有京东卡、遮阳伞等大量好礼等你来抽~ 明天（7月31日），北信瑞丰基金以及长信基金将带来两场直播，讲述下半年光伏、军工板块的投资机会，欢迎预约观 看哦~ 7月31日（周四）14：30 主题：《光伏板块下半年还有机会吗》 时间：7月31日 14：30 点击下方链接即可预约↓ 还有好礼等你赢！ 分享、点赞、在看 顺手三连越来越有钱 7月31日（周四）15：30 主题：《军工布局窗口打开了吗》 时间：7月31日 15：30 点击下方链接即可预约↓ 免责声明 以上观点来自相关机构，不代表天天基金的观点，不对观点的准确性和完整性做任何保证。 收益率数据仅供参考，过往业绩和走势风格不预示未来表现，不构成投资建议。转引的相关 ↓ 点击"阅读原文" 预约查看更多直播 ...

Core Viewpoint - The article discusses the recent performance of the A-share market, highlighting a recovery in the Shanghai Composite Index after a political bureau meeting that released positive signals for the economy and investment opportunities in the innovative pharmaceutical sector [1][2][8]. Group 1: A-share Market Performance - The A-share market experienced a pullback but rebounded in the afternoon, with the Shanghai Composite Index closing in the green, reaching a new high for the year [2][7]. - The market showed significant structural differentiation, with consumer and banking sectors rising while technology and new energy sectors faced declines [6][7]. - The trading volume exceeded 1.84 trillion yuan, indicating active market participation [5]. Group 2: Political Bureau Meeting Insights - The Central Political Bureau meeting emphasized the need to "stably resolve local government debt risks" and introduced a roadmap for "clearing financing platforms," alleviating systemic risk concerns [9]. - The meeting also highlighted the importance of stimulating domestic demand and implementing actions to boost consumption, positively impacting sectors like tourism, retail, and food and beverage [10]. - A focus on technological innovation was reiterated, aiming to foster new competitive industries and integrate technological advancements with industrial development [12]. Group 3: Investment Opportunities in Innovative Pharmaceuticals - A significant number of funds have achieved over 100% returns this year, particularly in the innovative pharmaceutical sector, with several funds listed showing substantial year-to-date performance [17]. - Fund managers suggest a cautious yet optimistic approach to the innovative pharmaceutical sector, advising investors to match risk and return expectations and avoid excessive chasing of high-flying stocks [18][19]. - Key guidelines for selecting funds include focusing on long-term performance stability, understanding investment strategies, and aligning with personal risk preferences [20].

Core Viewpoint - The article emphasizes the importance of utilizing proactive fiscal policies to enhance economic performance and stability, focusing on measures such as issuing long-term special bonds and local government bonds to stimulate growth and improve microeconomic circulation [1][2]. Group 1: Fiscal Policy Measures - The Ministry of Finance plans to accelerate the issuance and utilization of ultra-long-term special bonds and local government special bonds to create tangible work volume as soon as possible [1]. - A total of 14.1 trillion yuan was spent from the national general public budget in the first half of the year, ensuring strong support for key areas [1]. - By the end of June, the central government had allocated 9.29 trillion yuan in transfer payments to local governments, with over 90% of central budget investments disbursed [1]. Group 2: Debt Management and Economic Support - The Ministry of Finance has implemented a one-time increase of 6 trillion yuan in the debt limit for 2024, with 3.8 trillion yuan in new replacement bonds issued by the end of June [2]. - The average interest cost of replaced debt has decreased by over 2.5 percentage points, significantly alleviating repayment pressure and freeing up more funds for development and public needs [2]. - The focus is on promoting consumption to expand domestic demand, with policies aimed at enhancing service consumption in areas such as elderly care, childcare, culture, and tourism [2]. Group 3: Social Spending and Employment Support - In 2025, the budget for education, social security, and employment is set to be nearly 4.5 trillion yuan, with year-on-year growth of 6.1% and 5.9% respectively [3]. - The central government has allocated 1.1 trillion yuan for basic pension insurance subsidies, ensuring timely and full payment of pensions [3]. - Policies to support employment, such as job retention subsidies and tax reductions, are being strengthened to protect key groups in the labor market [3]. Group 4: Fiscal and Tax System Reform - The article discusses the need for a modern budget system and improved budget management practices to enhance local fiscal autonomy [4]. - There are plans to optimize the consumption tax system and improve the value-added tax refund policy to align with new business models [4]. - The Ministry of Finance is promoting zero-based budgeting reforms at the central level to support local governments in similar reforms [4].

Core Viewpoint - The International Monetary Fund (IMF) describes the global economic situation as "maintaining fragile resilience amid ongoing uncertainty," with projected growth rates for 2025 and 2026 slightly increased compared to previous forecasts [1][3]. Economic Growth Projections - The IMF forecasts global economic growth rates of 3.0% in 2025 and 3.1% in 2026, reflecting an increase of 0.2 and 0.1 percentage points respectively from earlier predictions [1]. - Emerging markets and developing economies are expected to grow at rates of 4.1% and 4.0% in 2025 and 2026, with China's growth rate for 2025 adjusted up by 0.8 percentage points to 4.8% [7]. Inflation Expectations - Global inflation is projected to decline, with rates expected to reach 4.2% in 2025 and 3.6% in 2026, although significant disparities exist among different economies [1][10]. - The IMF anticipates that U.S. inflation will remain above the 2% target level, while inflation in the Eurozone is expected to be more moderate [10]. Trade Volume Adjustments - The IMF has raised its 2025 global trade volume forecast by 0.9 percentage points but lowered the 2026 forecast by 0.6 percentage points, citing increased uncertainty in trade policies [4]. - A weaker dollar is expected to amplify tariff impacts rather than mitigate them, with U.S. fiscal policies potentially offsetting some negative effects on the current account balance [4][5]. Fiscal Vulnerabilities - The IMF warns of increasing global fiscal vulnerabilities, with some economies, including Brazil, France, and the U.S., projected to face significant fiscal deficits amid historically high public debt levels [5]. - Concerns over fiscal sustainability may lead to increased term premiums, particularly in the U.S., tightening global financial conditions and potentially causing market volatility [5].

Group 1 - Significant inflow into Chinese stock ETFs in overseas markets, with five major ETFs collectively attracting nearly $3 billion in net inflows since July [1][3] - The MSCI China ETF-iShares saw its asset size grow from $6.395 billion at the end of June to $7.187 billion by July 25, marking a 12.38% increase [3] - The Korean retail investors' enthusiasm for Chinese stocks is rising, with a cumulative trading volume of $5.764 billion in 2023, making China the second-largest overseas stock investment destination for Korean investors [4] Group 2 - Multiple foreign financial institutions express optimism about the value re-evaluation of Chinese assets, citing factors such as stable GDP growth and a recovering Hong Kong IPO market [6][7] - Goldman Sachs reports that the MSCI China Index and the CSI 300 Index have reached near four-year highs, indicating an 11% potential upside in the next 12 months [7] - Allianz Fund's research head believes that the current valuation of domestic assets has returned to historical averages but remains relatively cheap compared to overseas assets [7]